<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Nucl Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin Nucl Med</journal-id>
      <journal-id journal-id-type="publisher-id">RLU</journal-id>
      <journal-title-group>
        <journal-title>Clinical Nuclear Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0363-9762</issn>
      <issn pub-type="epub">1536-0229</issn>
      <publisher>
        <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27607171</article-id>
      <article-id pub-id-type="pmc">5065055</article-id>
      <article-id pub-id-type="publisher-id">RLU50574</article-id>
      <article-id pub-id-type="doi">10.1097/RLU.0000000000001357</article-id>
      <article-id pub-id-type="art-access-id">00016</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Interesting Images</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>High Uptake of FDG Along a Biliary Stent</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Nagasaki</surname>
            <given-names>Yasunari</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yamane</surname>
            <given-names>Hiromichi</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ochi</surname>
            <given-names>Nobuaki</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Honda</surname>
            <given-names>Yoshihiro</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takigawa</surname>
            <given-names>Nagio</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">&#x2020;</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">From the *Clinical Education and Training Center, Kawasaki Hospital, Kawasaki Medical School, Nakasange, Okayama; and &#x2020;Department of General Internal Medicine 4, Kawasaki Medical School, Nakasange, Okayama, Japan.</aff>
      <author-notes>
        <corresp id="cor1">Correspondence to: Hiromichi Yamane, MD, PhD, 2-1-80, Nakasange, Kita-ku, Okayama 700&#x2013;8505, Japan. E-mail: <email>hiromichi.ya@gmail.com</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>06</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <volume>41</volume>
      <issue>11</issue>
      <fpage>890</fpage>
      <lpage>891</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>5</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>7</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2016 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American College of Nuclear Medicine. All rights reserved.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <copyright-holder>Wolters Kluwer Health, Inc. All rights reserved.</copyright-holder>
        <license>
          <license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="rlu-41-890.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>A 66-year-old woman presented with abdominal discomfort. Contrast-enhanced CT revealed a mass in the pancreas and multiple liver metastases. Pathological examination confirmed the mass to be primary pancreatic cancer. Endoscopic insertion of a biliary stent was performed to prevent common bile duct obstruction. Subsequently, she received combination chemotherapy, which resulted in a complete response. FDG-PET-CT after chemotherapy revealed a high uptake of FDG along the outline of the biliary stent, with complete disappearance of both the primary and metastatic tumors.</p>
      </abstract>
      <kwd-group>
        <title>Key Words</title>
        <kwd>biliary stent</kwd>
        <kwd>chemotherapy</kwd>
        <kwd>FDG-PET-CT</kwd>
        <kwd>pancreatic cancer</kwd>
      </kwd-group>
      <counts>
        <page-count count="0"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <fig id="FU1" position="float">
      <label>FIGURE 1</label>
      <caption>
        <p><bold>A</bold>, A 66-year-old woman presented with abdominal discomfort. Contrast-enhanced computed tomography (CT) revealed a mass in her pancreas, with multiple liver metastases. Fine-needle aspiration biopsy during endoscopic retrograde cholangiopancreatography confirmed primary pancreatic cancer. <bold>B</bold>, Endoscopic insertion of a metallic biliary stent was performed to prevent common bile duct obstruction. Subsequently, she received 12 cycles of combination chemotherapy consisting of folic acid, bolus and continuous 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX),<sup><xref rid="bib1" ref-type="bibr">1</xref></sup> which resulted in a complete response.</p>
      </caption>
      <graphic xlink:href="rlu-41-890-g001"/>
    </fig>
    <fig id="FU2" position="float">
      <label>FIGURE 2</label>
      <caption>
        <p>FDG-PET-CT after chemotherapy revealed a high uptake of FDG along the outline of the biliary stent, with complete disappearance of both the primary and metastatic tumors. FDG-PET is useful for detecting inflammatory biliary and pancreatic diseases, including cancer.<sup><xref rid="bib2" ref-type="bibr">2</xref>&#x2013;<xref rid="bib4" ref-type="bibr">4</xref></sup> Typically, FDG-PET-CT has a high sensitivity for detecting cholangiocarcinoma or pancreatic diseases, including malignant neoplasm, and a negative scan indicates a nonmalignant state of disease, even if there is the presence of a small tumor.<sup><xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib5" ref-type="bibr">5</xref></sup> However, in the case of nonmalignant disease&#x2014;for example, autoimmune pancreatitis, including IgG4-related autoimmune pancreatitis, and autoimmune cholangitis&#x2014;it has been reported that FDG uptake was increased in diseased regions.<sup><xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib6" ref-type="bibr">6</xref></sup> In the present case, the finding of a high FDG uptake clearly indicates the outline of the biliary stent without any evidence of cancer involvement. Furthermore, cancer involvement was not shown pathologically after repeated endoscopic examinations.<sup><xref rid="bib7" ref-type="bibr">7</xref></sup> We suspect that this radiological finding may be related to the endoscopic procedure of biliary stent insertion, the major cause being the focal inflammation surrounding the metallic stent.<sup><xref rid="bib8" ref-type="bibr">8</xref></sup> The rate of complete remission (CR) among patients with advanced pancreatic cancer who are treated with FOLFIRINOX is approximately 0.6%.<sup><xref rid="bib1" ref-type="bibr">1</xref></sup> In general, biliary tract cancer and pancreatic cancer have a poor prognosis and are thought to be one of the most intractable malignant tumors. The reported rate of CR of advanced biliary tract cancer is only 2% of patients who are treated with combined chemotherapy consisting of gemcitabine and oxaliplatin.<sup><xref rid="bib9" ref-type="bibr">9</xref></sup> We suggest that residual high uptake of FDG along the biliary stent can be considered to be caused by local inflammation if the initial tumors have been cured by chemotherapy and complete remission has been achieved. Physicians should be aware of this phenomenon because these findings make adequate diagnosis of these cancers difficult. Detailed observation of the clinical course and repetition of the radiological and pathological examinations might help swift and correct diagnosis.</p>
      </caption>
      <graphic xlink:href="rlu-41-890-g002"/>
    </fig>
  </body>
  <back>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>Conflicts of interest and sources of funding: none declared.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="bib1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Desseigne</surname><given-names>F</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</article-title>. <source><italic>N Engl J Med</italic></source>. <year>2011</year>;<volume>364</volume>:<fpage>1817</fpage>&#x2013;<lpage>1825</lpage>.<pub-id pub-id-type="pmid">21561347</pub-id></mixed-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Alkhawaldeh</surname><given-names>K</given-names></name><name><surname>Faltten</surname><given-names>S</given-names></name><name><surname>Biersack</surname><given-names>HJ</given-names></name><etal/></person-group>
<article-title>The value of F-18 FDG PET in patients with primary sclerosing cholangitis and cholangiocarcinoma using visual and semiquantitative analysis</article-title>. <source><italic>Clin Nucl Med</italic></source>. <year>2011</year>;<volume>36</volume>:<fpage>879</fpage>&#x2013;<lpage>883</lpage>.<pub-id pub-id-type="pmid">21892037</pub-id></mixed-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Autoimmune pancreatitis: whole-body 18F-FDG PET/CT findings</article-title>. <source><italic>Abdom Imaging</italic></source>. <year>2013</year>;<volume>38</volume>:<fpage>543</fpage>&#x2013;<lpage>549</lpage>.<pub-id pub-id-type="pmid">23223832</pub-id></mixed-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Kawada</surname><given-names>N</given-names></name><name><surname>Uehara</surname><given-names>H</given-names></name><name><surname>Hosoki</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors</article-title>. <source><italic>Pancreas</italic></source>. <year>2015</year>;<volume>44</volume>:<fpage>655</fpage>&#x2013;<lpage>659</lpage>.<pub-id pub-id-type="pmid">25815646</pub-id></mixed-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Patel</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name></person-group>
<article-title>FDG-PET/CT manifestation of tumor seeding along percutaneous biliary drainage catheter tract</article-title>. <source><italic>Clin Nucl Med</italic></source>. <year>2015</year>;<volume>40</volume>:<fpage>830</fpage>&#x2013;<lpage>831</lpage>.<pub-id pub-id-type="pmid">26098291</pub-id></mixed-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Utility of FDG-PET/CT in the diagnosis of IgG4-related diseases</article-title>. <source><italic>Clin Exp Rheumatol</italic></source>. <year>2016</year>;<volume>34</volume>:<fpage>119</fpage>&#x2013;<lpage>125</lpage>.<pub-id pub-id-type="pmid">26842851</pub-id></mixed-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>McGuire</surname><given-names>DE</given-names></name><name><surname>Venu</surname><given-names>RP</given-names></name><name><surname>Brown</surname><given-names>RD</given-names></name><etal/></person-group>
<article-title>Brush cytology for pancreatic carcinoma: an analysis of factors influencing results</article-title>. <source><italic>Gastrointest Endosc</italic></source>. <year>1996</year>;<volume>44</volume>:<fpage>300</fpage>&#x2013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">8885350</pub-id></mixed-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Lin</surname><given-names>EC</given-names></name><name><surname>Studley</surname><given-names>M</given-names></name></person-group>
<article-title>Biliary tract FDG uptake secondary to stent placement</article-title>. <source><italic>Clin Nucl Med</italic></source>. <year>2003</year>;<volume>28</volume>:<fpage>318</fpage>&#x2013;<lpage>319</lpage>.<pub-id pub-id-type="pmid">12642714</pub-id></mixed-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Gruenberger</surname><given-names>B</given-names></name><name><surname>Schueller</surname><given-names>J</given-names></name><name><surname>Heubrandtner</surname><given-names>U</given-names></name><etal/></person-group>
<article-title>Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study</article-title>. <source><italic>Lancet Oncol</italic></source>. <year>2010</year>;<volume>11</volume>:<fpage>1142</fpage>&#x2013;<lpage>1148</lpage>.<pub-id pub-id-type="pmid">21071270</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
